Predictive Value Of Admission Blood Glucose Level In Patients With Acute Myocardial Infarction

Assiut University

Status: Unknown

Conditions: Predictive Value of Admission Blood Glucose Level in Acute Myocardial Infarction

Treatments: Diagnostic Test: Blood Glucose Level

Study type: Observational

Funder types: Other

Identifiers

NCT03164707

Serum Blood Glucose Level

Details and patient eligibility

About

Coronary atherosclerosis is the leading cause of death worldwide. Diabetes mellitus is associated with increased prevalence of coronary artery disease

Increased plasma glucose is a common feature in the acute phase of myocardial infarction, even in patients without diabetes. Patients with stress hyperglycemia, but without previous diagnosis of diabetes, were at increased risk of congestive heart failure, arrhythmia and cardiogenic shock as well as increased both in-hospital and long-term mortality . Previous studies have demonstrated larger infarct size and poorer prognosis inpatients with hyperglycemia upon hospital admission compared with patients without hyperglycemia

It has been reported that stress hyperglycemia impairs microvascular circulation and may lead to no-reflow phenomenon. No reflow phenomenon was significantly more frequent among patients with hyperglycemia and increased progressively with increasing admission blood glucose in patients with Acute Myocardial Infarction . Furthermore, patients with high admission glucose are more likely to develop restenosis and require repeat revascularization procedures compared with those with normal admission glucose and are also at increased risk for repeated Myocardial Infarction, stent thrombosis and death.

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

acute ST Segment Elevation Myocardial Infarction patients not known to have Diabetes Mellitus undergoing primary PCI.

Exclusion criteria

• patients known to have Diabetes mellitus (known diabetes mellitus on admission, which was treated with diet, oral glucose-lowering medication, and/or insulin).
• Patients with prior Primary Percutaneous Intervention and/or Coronary Artery Bypass Graft (altering disease state).
• Patients with severe liver or renal disease (altering disease state).
• Patients with anemia, kidney disease or certain blood disorders (thalassemia).